Skip to main content
bioAffinity Technologies, Inc. logo

bioAffinity Technologies, Inc. - Investor Relations & Filings

Listed IPO Sep 2022
Ticker · BIAF ISIN · CA09064N1033 US Professional, scientific and technical activities
Open in API
Filings indexed 341 across all filing types
Latest filing 2025-09-30 Capital/Financing Update
Country US United States of America
Listing US BIAF · 1 venue

About bioAffinity Technologies, Inc.

https://bioaffinitytech.com/

bioAffinity Technologies, Inc. is a company focused on developing noninvasive diagnostics and targeted therapeutics for cancer. Its first commercialized product, CyPath® Lung, is a non-invasive laboratory developed test for the early detection of lung cancer. The test is designed for individuals at high risk who have suspicious but indeterminate findings on a low-dose computed tomography (LDCT) scan. CyPath® Lung analyzes patient sputum samples using an automated flow cytometry platform and machine learning to identify cell populations indicative of cancer. This approach aims to improve diagnostic accuracy, reduce unnecessary invasive procedures, and lower associated healthcare costs. The company's core technology is based on a proprietary porphyrin platform that preferentially targets cancer cells, with ongoing research to expand its application to other diagnostics and therapeutics.

Recent filings

Filing Released Lang Actions
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(4) under the Securities Act, describing an offering of common stock and pre-funded warrants by bioAffinity Technologies, Inc. It includes detailed information about the offering terms, Nasdaq listing compliance issues, reverse stock split, use of proceeds, risk factors, and plan of distribution. This type of document is a registration statement prospectus related to capital raising activities. It is not an annual or quarterly report, earnings release, or management discussion. It is not a proxy, voting results, or governance document. It is not a legal proceeding or merger announcement. The document is clearly a capital raising disclosure and financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is the actual offering prospectus, not just an announcement of a report, so it is not RPA or RNS.
2025-09-30 English
Regulatory Filings 2025
Regulatory Filings
2025-09-30 English
3
Director's Dealing
2025-09-25 English
3
Director's Dealing
2025-09-25 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC, which is a regulatory filing used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the securities being offered, the offering process, Nasdaq listing compliance issues, and the terms of the offering. This is not a financial report, earnings release, or management discussion, but a regulatory filing related to capital raising and securities registration. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or certification.
2025-09-25 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated September 24, 2025. It is a registration statement under the Securities Act of 1933 for the offering of common stock and warrants by bioAffinity Technologies, Inc. The text includes detailed information about the securities being offered, pricing, placement agent fees, and other offering details. This type of filing is used for initial public offerings or other securities offerings to register the securities with the SEC. It is not an annual report, earnings release, or other financial report, but a capital raising document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or notice, so it is not RPA or RNS. Confidence is high due to the clear identification of the form and content.
2025-09-24 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.